作者: Thankamma Ajithkumar , Naduni Imbulgoda , Elliott Rees , Fiona Harris , Gail Horan
关键词:
摘要: The 2016 World Health Organization (WHO) classification of primary central nervous system (CNS) tumors includes numerous uncommon (representing ≤1% tumors) low-grade (grades I-II) brain neoplasms with varying clinical behaviors and outcomes. Generally, gross tumor or maximal safe resection is the treatment. Adjuvant treatments, though their exact role unknown, may be considered individually based on pathological subtypes a proper assessment risks benefits. Targetable mutations such as BRAF (proto-oncogene B-Raf), TRAIL (tumor necrosis factor apoptosis inducing ligand), PDGFR (platelet derived growth receptor) have promising roles in future management.